Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Early electronic advance directives reduce burdensome end-of-life care

20

May 2026

Early electronic advance directives reduce burdensome end-of-life care

Advance directives document patient preferences for future care, including end-of-life. An analysis in the Journal of the American Geriatrics Society found that older patients with an advance directive that had been uploaded into the electronic health record at least six months before death were 25% less likely to experience potentially burdensome end-of-life care (19.9% versus 26.8%) and 31% less likely to have died in the hospital (23.2% versus 32.1%).

Bedfont® Scientific targets international growth at EAACI Congress 2026

20

May 2026

Bedfont® Scientific targets international growth at EAACI Congress 2026

Bedfont® Scientific Ltd., an innovative leader in the medical breath analysis industry with almost 50 years of experience, is pleased to join thousands of healthcare experts at this year’s European Academy of Allergy and Clinical Immunology (EAACI) Congress 2026 at stand I03 to showcase its NObreath® and Gastrolyzer® range of non-invasive breath analysis devices.

Digital pens and tablets could offer non-invasive tools for routine dementia screening

20

May 2026

Digital pens and tablets could offer non-invasive tools for routine dementia screening

Handwriting requires a combination of fine motor control and a complex set of mental skills, such as selecting, organizing, and interpreting sensory information, making it a cognitively challenging task. Because of its high demand on the brain, it is a potential marker of cognitive decline, especially as we age. Then, our handwriting often becomes slower or choppier.

How food and alcohol cues leave different signatures in the brain

20

May 2026

How food and alcohol cues leave different signatures in the brain

Food and alcohol cues appear to engage partially distinct EEG oscillatory patterns, with food cues linked mainly to increased delta activity and alcohol-related processing showing alpha and delta differences in key contrasts. The effects were strongest in participants with relatively higher AUDIT scores, but neural changes were small and subjective cue responses were more robust.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.